

Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test Manufacturing Overview

Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test is being manufactured in cooperation with Jiangsu Dablood Pharmaceutical CO, Ltd. Dablood Pharmaceutical has successfully distributed 38 million tests to date throughout Asia and Europe. To the best of Predictive's knowledge, Dablood Pharmaceutical is one of very few companies approved by the Chinese government to co-develop and manufacture rapid antibody tests. Dablood Pharmaceutical is one of the largest diagnostic kit manufacturers in China and is currently producing up to 1.5 million units of the rapid antibody test per day in China.

Predictive evaluated other potential developers and suppliers and believes Dablood Pharmaceutical provides not only existing inventory, its high-volume production capacity enables them to rapidly increase production to provide high-quality tests to meet rapidly expanding global demand.

Dablood Pharmaceutical has been recognized by the Chinese government for its effort of developing and producing testing products to help detect the COVID-19 and has received approval for distribution of its test across the domestic Chinese market and the European Union with a CE mark.